John Throup

2.9k total citations · 2 hit papers
32 papers, 2.2k citations indexed

About

John Throup is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, John Throup has authored 32 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 14 papers in Immunology and 11 papers in Oncology. Recurrent topics in John Throup's work include Psoriasis: Treatment and Pathogenesis (12 papers), Cytokine Signaling Pathways and Interactions (9 papers) and Bacterial Genetics and Biotechnology (5 papers). John Throup is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (12 papers), Cytokine Signaling Pathways and Interactions (9 papers) and Bacterial Genetics and Biotechnology (5 papers). John Throup collaborates with scholars based in United States, United Kingdom and Canada. John Throup's co-authors include Paul Williams, Gordon S.A.B. Stewart, Simon Swift, Barrie W. Bycroft, Siri Ram Chhabra, Michael K. Winson, George P. C. Salmond, Steve Atkinson, Martin Burnham and Subhashis Banerjee and has published in prestigious journals such as Nature Biotechnology, Biochemistry and Trends in Biochemical Sciences.

In The Last Decade

John Throup

31 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial

2022 219 citations April W. Armstrong, Melinda Gooderham et al. Journal of the American Academy of Dermatology profile →
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial

2022 173 citations Bruce Strober, Diamant Thaçi et al. Journal of the American Academy of Dermatology profile →

Peers

Countries citing papers authored by John Throup

Since Specialization

Citations

This map shows the geographic impact of John Throup's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Throup with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Throup more than expected).

Fields of papers citing papers by John Throup

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Throup. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Throup. The network helps show where John Throup may publish in the future.

Co-authorship network of co-authors of John Throup

This figure shows the co-authorship network connecting the top 25 collaborators of John Throup. A scholar is included among the top collaborators of John Throup based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Throup. John Throup is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A SMALL MOLECULE SLC6A19 INHIBITOR INCREASES URINARY PHENYLALANINE EXCRETION AND REDUCES ITS PATHOGENIC PLASMA ACCUMULATION IN A PHENYLKETONURIA MOUSE MODEL 2023 ·Molecular Genetics and Metabolism ·Heike J. Wobst, (unknown), Giovanni Muncipinto, (unknown), (unknown), Andreu Viader, (unknown), Dean G. Brown, Nick Pullen, John Throup, Joel C. Barrish	4
2	Treatment of Plaque Psoriasis with Deucravacitinib (Poetyk Pso-2 Study): A Plain Language Summary 2023 ·Immunotherapy ·Bruce Strober, Diamant Thaçi, Howard Sofen, Leon Kircik, Kenneth B. Gordon, Peter Foley, Phoebe Rich, C. Paul, Jerry Bagel, (unknown), John Throup, Sudeep Kundu, (unknown), Misti Linaberry, Subhashis Banerjee, Kim Papp	2
3	Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial breakdown → 2022 ·Journal of the American Academy of Dermatology ·April W. Armstrong, Melinda Gooderham, Richard B. Warren, Kim Papp, Bruce Strober, Diamant Thaçi, Akimichi Morita, Jacek C. Szepietowski, Shinichi Imafuku, (unknown), John Throup, Sudeep Kundu, Steve Schoenfeld, Misti Linaberry, Subhashis Banerjee, Andrew Blauvelt	219
4	Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial breakdown → 2022 ·Journal of the American Academy of Dermatology ·Bruce Strober, Diamant Thaçi, Howard Sofen, Leon Kircik, Kenneth B. Gordon, Peter Foley, Phoebe Rich, C. Paul, Jerry Bagel, (unknown), John Throup, Sudeep Kundu, (unknown), Misti Linaberry, Subhashis Banerjee, Kim Papp	173
5	34658 Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe plaque psoriasis who had inadequate responses to apremilast at week 24 in the phase 3 POETYK PSO-1 and PSO-2 trials 2022 ·Journal of the American Academy of Dermatology ·April W. Armstrong, Richard B. Warren, Howard Sofen, Lynda Spelman, Craig L. Leonardi, Subhashis Banerjee, Tao Wang, John Throup, Elizabeth Colston, Andrew Napoli, Alexa B. Kimball	2
6	Lack of Electrocardiographic Effects of Deucravacitinib in Healthy Subjects 2022 ·Clinical Pharmacology in Drug Development ·Anjaneya Chimalakonda, Shalabh Singhal, Raymond B. Darbenzio, Randy Dockens, (unknown), Subhashis Banerjee, Ihab Girgis, John Throup, Bing He, (unknown), Bindu Murthy	11
7	Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors 2021 ·Dermatology and Therapy ·Anjaneya Chimalakonda, James R. Burke, Lihong Cheng, Ian M. Catlett, Michael Tagen, Qihong Zhao, (unknown), Jun Shen, Ihab Girgis, Subhashis Banerjee, John Throup	88
8	Modeling and Simulation of the Pharmacokinetics and Target Engagement of an Antagonist Monoclonal Antibody to Interferon‐γ–Induced Protein 10, BMS‐986184, in Healthy Participants to Guide Therapeutic Dosing 2020 ·Clinical Pharmacology in Drug Development ·Weiguo Cai, Tarek A. Leil, Leonid Gibiansky, Murli Krishna, Hongwei Zhang, Huidong Gu, Huadong Sun, John Throup, Subhashis Banerjee, Ihab Girgis	3
9	Population Pharmacokinetic Analysis of BMS‐986166, a Novel Selective Sphingosine‐1‐Phosphate‐1 Receptor Modulator, and Exposure‐Response Assessment of Lymphocyte Counts and Heart Rate in Healthy Participants 2020 ·Clinical Pharmacology in Drug Development ·(unknown), Shalabh Singhal, Diane E. Shevell, Huadong Sun, Jenny Xie, (unknown), (unknown), Santanu Dutta, Elizabeth Ludwig, Hannah Huang, (unknown), Aberra Fura, John Throup, Ihab Girgis	1
10	5 Oral selective tyrosine kinase 2 (TYK2) inhibition with BMS-986165 in patients with systemic lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study (PAISLEY) 2019 ·Abstracts ·Shalabh Singhal, Vaishali Shah, (unknown), (unknown), (unknown), John Throup, Subhashis Banerjee, Joan T. Merrill	3
11	P638 BMS-986165, an oral selective tyrosine kinase 2 (TYK2) inhibitor, does not affect the pharmacokinetics of methotrexate in healthy subjects 2019 ·Journal of Crohn s and Colitis ·Anjaneya Chimalakonda, (unknown), Randy Dockens, John Throup, Subhashis Banerjee, Ihab Girgis	3
12	THU0190 THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF BMS-986166, A NOVEL, SELECTIVE, PARTIAL AGONIST OF THE SPHINGOSINE-1-PHOSPHATE (S1P) SUBTYPE 1 RECEPTOR IN HEALTHY PARTICIPANTS 2019 ·Annals of the Rheumatic Diseases ·Shalabh Singhal, Ihab Girgis, Jenny Xie, Santanu Dutta, Diane E. Shevell, John Throup	3
13	Effects of Urotensin II Receptor Antagonist, GSK1440115, in Asthma 2013 ·Frontiers in Pharmacology ·(unknown), Sanjay Kumar, David J. Behm, (unknown), Robert Noble, John Throup, (unknown)	10
14	Biochemical Characterization of the First Essential Two-Component Signal Transduction System from <i>Staphylococcus aureus</i> and <i>Streptococcus pneumoniae</i> 2003 ·Microbial Physiology ·Valerie A. Clausen, (unknown), John Throup, Martin Burnham, Martin Rosenberg, Nicola G. Wallis	30
15	A genomic analysis of two‐component signal transduction in Streptococcus pneumoniae 2000 ·Molecular Microbiology ·John Throup, Kristin K. Koretke, Alexander P. Bryant, Karen Ingraham, Alison F. Chalker, Yigong Ge, Andrea Marra, Nicola G. Wallis, James R. Brown, David Holmes, Martin Rosenberg, Martin Burnham	261
16	A hierarchical quorum‐sensing system in Yersinia pseudotuberculosis is involved in the regulation of motility and clumping 1999 ·Molecular Microbiology ·Steve Atkinson, John Throup, Gordon S.A.B. Stewart, Paul Williams	142
17	Plants genetically modified to produce N-acylhomoserine lactones communicate with bacteria 1999 ·Nature Biotechnology ·Rupert G. Fray, John Throup, Mavis Daykin, Andrew D. Wallace, Paul Williams, Gordon S.A.B. Stewart, Donald Grierson	96
18	Construction and analysis ofluxCDABE-based plasmid sensors for investigatingN-acyl homoserine lactone-mediated quorum sensing 1998 ·FEMS Microbiology Letters ·Michael K. Winson, Simon Swift, (unknown), John Throup, (unknown), Siri Ram Chhabra, Barrie W. Bycroft, Paul Williams, Gordon S.A.B. Stewart	488
19	Characterisation of the yenI/yenR locus from Yersinia enterocolitica mediating the synthesis of two N‐acylhomoserine lactone signal molecules 1995 ·Molecular Microbiology ·John Throup, Miguel Cámara, Geoffrey S. Briggs, Michael K. Winson, Siri Ram Chhabra, Barrie W. Bycroft, Paul Williams, Gordon S.A.B. Stewart	125
20	A novel strategy for the isolation of luxl homologues: evidence for the widespread distribution of a LuxR:Luxl superfamily in enteric bacteria 1993 ·Molecular Microbiology ·Simon Swift, Michael K. Winson, Pan F. Chan, Nigel J. Bainton, (unknown), Philip J. Reeves, Catherine Rees, Siri Ram Chhabra, Philip J. Hill, John Throup, Barrie W. Bycroft, George P. C. Salmond, Paul Williams, Gordon S.A.B. Stewart	169

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact